RCLARITY : A Prospective Phase II Study of Rituximab Combined With Lenalidomide and Chidamide ( RLC ) for the Treatment of Relapsed/Refractory Angioimmunoblastic T‐Cell Lymphoma

Documenti analoghi

• Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
  di: Meirav Kedmi, et al.
  Pubblicazione: (2024)
• Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
  di: Yoshikazu Ikoma, et al.
  Pubblicazione: (2025)
• Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
  di: Giacomo Loseto, et al.
  Pubblicazione: (2025)
• Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma
  di: Alyssa Bouska, et al.
  Pubblicazione: (2025)
• Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
  di: Inna Y. Gong, et al.
  Pubblicazione: (2026)